Recruiting Chronic Lymphocytic Leukemia Studies in Palo Alto
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment...
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
The main objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic lymphocytic leukemia (CLL)...
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia...
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
The study is a global, multi-center safety and efficacy trial of epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20). Epcoritamab will be tested either in Relapsed/refract...
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (S...
About Chronic Lymphocytic Leukemia Clinical Trials in Palo Alto
Chronic lymphocytic leukemia (CLL) is a slow-growing cancer of the blood and bone marrow that affects B lymphocytes. It is the most common type of adult leukemia. Treatment options include targeted therapies, chemotherapy, and immunotherapy.
There are currently 5 chronic lymphocytic leukemia clinical trials recruiting participants in Palo Alto, CALIFORNIA. These studies are seeking a combined 2,617 participants. Research is being sponsored by Loxo Oncology, Inc., BeiGene, Genmab. Clinical trial participation is free and participants receive study-related medical care at no cost.
Chronic Lymphocytic Leukemia Clinical Trials in Palo Alto — FAQ
Are there chronic lymphocytic leukemia clinical trials in Palo Alto?
Yes, there are 5 chronic lymphocytic leukemia clinical trials currently recruiting in Palo Alto, CALIFORNIA. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Palo Alto?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Palo Alto research site will contact you about next steps.
Are clinical trials in Palo Alto free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Palo Alto studies also compensate for your time and travel.
What chronic lymphocytic leukemia treatments are being tested?
The 5 active trials in Palo Alto are testing new therapies including novel drugs, biologics, and treatment approaches for chronic lymphocytic leukemia.
Data updated March 2, 2026 from ClinicalTrials.gov